文献速递眼底病与葡萄膜炎神经眼科

无自述视觉症状的黑色素瘤患者中的TRPM1自身抗体

TRPM1 Autoantibodies in Melanoma Patients Without Self-Reported Visual Symptoms.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2019-01-01

本研究检测15例无自述视觉症状的皮肤恶性黑色素瘤(CMM)患者血清,采用三种方法检测抗TRPM1自身抗体,其中5例至少一种方法阳性;50例非已知癌症对照血清中1例与TRPM1肽弱反应。作者认为抗TRPM1自身抗体可见于无自述视觉症状的CMM患者,其存在可能使患者易患黑色素瘤相关视网膜病变(MAR)。

要点

  • 15例无自述视觉症状的CMM患者中5例至少一种检测抗TRPM1自身抗体阳性。
  • 50例非已知癌症对照血清中1例与TRPM1肽弱反应。
  • 多数患者为晚期(III和IV期)疾病并正接受包括免疫治疗在内的积极治疗。

核心结论

  • 抗TRPM1自身抗体存在于无自述视觉症状的CMM患者血清中。
  • 多数患者为晚期(III和IV期)疾病并正接受包括免疫治疗在内的积极治疗。
  • 免疫治疗是否影响TRPM1自身抗体的表达尚不清楚。
  • TRPM1自身抗体的存在可能使患者易患MAR。

研究设计与样本

  • 研究检测15例CMM患者的血清样本,采用三种检测方法:TRPM1转染HEK细胞的免疫荧光标记、野生型与TRPM1敲除小鼠视网膜切片的免疫荧光标记、细菌表达的重组TRPM1肽的免疫印迹检测。
  • 对照为50例非已知癌症患者的血清。

主要发现

  • 15例无自述视觉症状的CMM患者中,5例血清在三种检测中至少一种呈抗TRPM1自身抗体阳性。
  • 50例非已知癌症对照血清中,1例与TRPM1肽呈弱反应。

局限性

  • 免疫治疗是否影响TRPM1自身抗体的表达尚不清楚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Melanoma-associated retinopathy (MAR) is a paraneoplastic syndrome associated with cutaneous malignant melanoma (CMM). Visual symptoms include night blindness, photopsia, and reduced-contrast sensitivity. An abnormal ERG b-wave and the presence of anti-bipolar cell autoantibodies, including autoantibodies reacting with the ON-bipolar cell TRPM1 channel, help to confirm the diagnosis. The goal of this study was to determine if CMM patients without visual symptoms also express anti-TRPM1 autoantibodies. METHODS: Serum samples from 15 CMM patients were tested using three assays: immunofluorescent labeling of TRPM1-transfected HEK cells, immunofluorescent labeling of retinal sections from wild-type and TRPM1 knockout mice, and immunoblot detection of a bacterially produced recombinant TRPM1 peptide. RESULTS: Serum specimens from 5 of the 15 CMM patients without declared visual symptoms were positive for anti-TRPM1 autoantibodies in at least one of the three assays. One of 50 control sera from patients not known to have cancer was also weakly reactive with the TRPM1 peptide. CONCLUSIONS: Autoantibodies against TRPM1 are present in CMM patient sera without self-reported visual symptoms. Most patients had advanced (stage III and IV) disease and were undergoing aggressive treatments, including immunotherapy. It is unknown if immunotherapy affects the expression of TRPM1 autoantibodies. The presence of TRPM1 autoantibodies may predispose patients for MAR.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Duvoisin RM, Ren G, Haley TL, et al. TRPM1 Autoantibodies in Melanoma Patients Without Self-Reported Visual Symptoms. Invest Ophthalmol Vis Sci. 2019. PMID: 31117125. doi:10.1167/iovs.19-26775

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。